Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design

American Journal of Epidemiology

Volumn 157, Issue 2, 2003, Pages 158-165

  Ki, Moran ^a   Park, Taesung ^b   Yi, Sung Gon ^b   Oh, Jin Kyoung ^c   Choi, BoYoul ^c  

^a Eulji University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

Author keywords

Child, hospitalized; Epidemiologic research design; Infant; Meningitis, aseptic; Mumps vaccine; Vaccines

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

CHILD HEALTH; DESIGN; MENINGITIS; RISK ASSESSMENT; VACCINATION;

ARTICLE; ASEPTIC MENINGITIS; CHILD HOSPITALIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; INFANT; KOREA; MAJOR CLINICAL STUDY; MALE; MEASLES VACCINATION; PRESCHOOL CHILD; RISK ASSESSMENT;

CHILD, PRESCHOOL; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; KOREA; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MEDICAL RECORDS; MENINGITIS, ASEPTIC; RISK; SEASONS;

EID: 0037438619     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwf167     Document Type: Article

References (31)

1. Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental? Lancet 1998;351:611-12.
2. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of antivaccine movements on pertussis control: the untold story. Lancet 1998;351:356-61.
3. Korea Institute Health and Social Affairs. National fertility and family health survey 2000. (In Korean). Seoul, Korea: Korea Institute Health and Social Affairs, 2001. (Report no. 2000-01).
4. Miller E, Hill A, Morgan-Capner P, et al. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995;13:799-802.
5. Boulianne N, De Serres G, Ratman S, et al. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 1995;13:1611-16.
6. Toscani L, Batou M, Bouvier P, et al. Comparison of the protective efficacy of various strains of mumps vaccine: a study in schools. (In French). Soz Präventivmed 1996;41:341-7.
7. Nokes DJ, Anderson RM. Vaccine safety versus vaccine efficacy in mass immunisation programmes. Lancet 1991;338: 1309-12.
8. Mumps virus vaccines. Wkly Epidemiol Rec 2001;76:346-55.
9. Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 1991;10:209-13.
10. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993;341:979-82.
11. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995;345:567-9.
12. Dourado I, Cunha S, Teixeira MG, et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe- containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol 2000;151:524-30.
13. Fujinaga T, Youichi M, Hiroshi T, et al. A prefecture-wide survey of mumps meningitis associated with measles, mumps and rubella vaccine. Pediatr Infect Dis J 1991;10:204-9.
14. Ueda K, Miyazaki C, Hidaka Y, et al. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. (Letter). Lancet 1995;346:701-2.
15. Kimura M, Kuno-Sakai H, Yamazaki S, et al. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn 1996;38:205-11.
16. Furesz J, Contreras G. Vaccine-related mumps meningitis - Canada. Can Dis Wkly Rep 1990;16:253-4.
17. Rebiere I, Galy-Eyraud C. Estimation of the risk of aseptic meningitis associated with mumps vaccination, France, 1991- 1993. Int J Epidemiol 1995;24:1223-7.
18. Jonville-Béra AP, Autret E, Galy-Eyraud C, et al. Aseptic meningitis following mumps vaccine. A retrospective survey by the French Regional Pharmarcovigilence Centers and by Pasteur-Mérieux Sérums and Vaccines. Pharmacoepidemiol Drug Safety 1996;5:33-7.
19. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997;16:500-3.
20. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53.
21. Confavreux C, Suissa S, Saddier P, et al. Vaccination and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344: 319-26.
22. Institute of National Health Insurance. 1998: the statistics of health insurance. Seoul, Korea: Jin Sung Press, 1999.
23. Mittleman MA, Maclure M, Robins JM. Control sampling strategies for case-crossover studies: an assessment of relative efficiency. Am J Epidemiol 1995;142:91-8.
24. Ki M, Kim MH, Shin YJ, et al. MMR immunization rate and related factors. (In Korean). J Korean Pediatr Soc 2001;44:375-88.
25. Čižman M, Mozetič M, Radešček-Rakar R, et al. Aseptic meningitis after vaccination against measles and mumps. Pediatr Infect Dis J 1989;8:302-8.
26. Redelmeier DA, Tibshirani RJ. Interpretation and bias in case-crossover studies. J Clin Epidemiol 1997;50:1281-7.
27. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000;21:193-221.
28. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995;51:228-35.
29. Feldmann U. Epidemiologic assessment of risks of adverse reactions associated with intermittent exposure. Biometrics 1993;49:419-28.
30. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999;353:2026-9.
31. Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001;84: 227-9.